ArticleScientific reports2026
First serogroup Y meningitis outbreak in Hubei Province Central China linked to adolescent immunization gaps.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Meningococcal meningitis poses a persistent public health threat globally, with evolving epidemic serogroups complicating prevention especially in China in recent years. On May 27, 2024, Hubei Province (central China) reported its first laboratory-confirmed case of serogroup Y Meningococcal meningitis in a student aged 14 from L County, E City. This study aimed to characterize the outbreak, identify transmission drivers, and provide evidence for targeted control strategies. A field investigation was conducted involving case definition (suspected/probable/confirmed cases, carriers), epidemiological interviews (symptom onset, vaccination history, exposures), and laboratory testing. We analyzed 199 close contacts and expanded sampling population via nucleic acid testing and bacterial culture. Isolated serogroup Y strains were subjected to whole-genome sequencing, phylogenetic analysis, and antibiotic susceptibility testing. One confirmed serogroup Y meningococcal meningitis case and 13 Neisseria meningitidis (Nm) carriers (Five serogroup Y) were identified. The index case (an eighth grade student) had completed the national serogroup A / serogroups A and C meningococcal vaccination schedule (last dose: 2016), but serogroup Y vaccination was absent in the index case and all classmates. Nucleic acid testing positivity of Nm was 6.5% (13/199) among contacts and expanded sampling population, with 2.5% (5/199) serogroup Y carriers. All five serogroup Y isolates (LF-strains) belonged to ST-1655 (ST-23 clonal complex) and were phylogenetically close to strains from other Chinese provinces. Antibiotic susceptibility testing confirmed susceptibility to six antibiotics (Penicillin, Ampicillin, Ciprofloxacin, Ceftriaxone, Azithromycin and Rifampicin). Emergency ACYW135 vaccination achieved 57.5% coverage in the affected school, with no secondary cases. This is the first report of serogroup Y Meningococcal meningitis in Hubei Province, caused by the hyper-invasive ST-1655 (ST-23 clonal complex). Adolescent immunity gaps to serogroup Y were the primary driver. To combat meningococcal meningitis in China, we recommend integrating serogroup Y into routine vaccination especially for adolescents, strengthening serogroup-specific surveillance, and enhancing local laboratory capacity for rapid meningococcal meningitis diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.